摘要
Objective To analyze the effect of treatment with bevacizumab, an anti-VEGFR pathway drug, in patients with lung cancer. Methods 60 patients with lung cancer were used as samples, from October 2021 to February 2023, and random number table method was used to divide them into groups. Group A was treated with bevacizumab + paclitaxel protein-binding protein combined with carboplatin + cisplatin, and Group B was treated with paclitaxel protein-binding combined with carboplatin + cisplatin. Compare the differences in curative effect, tumor marker levels, immune function, toxic and side effects between the two groups. Results Lung cancer therapy in group A was higher than that in group B, P<0.05; serum tumor markers such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) in group A were significantly higher than those in group B Low, P<0.05; CD4 + , CD8 + , CD4 + /CD8 + and other immune indicators in group A were better than those in group B, P<0.05; the incidence of toxic and side effects in patients with lung cancer in group A was not different from that in group B, P>0.05. Conclusion Bevacizumab, an anti-VEGFR pathway drug, is effective and feasible in the treatment of lung cancer, which can inhibit the progression of cancer, regulate the body's immune function, reduce toxic and side effects, and prolong the survival of patients.
参考
Han Xue. Analysis of the value of bevacizumab as an anti-VEGFR pathway drug in the clinical treatment of lung cancer [J]. Medical Diet Therapy and Health, 2020, 18(6): 92-92, 95.
Huang Shufeng. Analysis of the value of bevacizumab injection as an anti-VEGFR pathway drug in the clinical treatment of lung cancer [J]. Chinese Science and Technology Journal Database (Full Text Edition) Medicine and Health, 2022, 5(4): 12-13 .
Zhu Yuanbin. The therapeutic value of bevacizumab as an anti-VEGFR pathway drug in the treatment of lung cancer patients [J]. Chinese Science and Technology Journal Database (Citation Edition) Medicine and Health, 2022, 4(2):47-50.
Yu Zhongping, Huang Xuefeng. The clinical value of bevacizumab as an anti-VEGFR pathway drug in advanced non-squamous non-small cell lung cancer [J]. China Practical Medical Journal, 2021, 48(2): 105-107.
Li Dong, Yue Chengshan, Hu Yong, Dong Xueliang, Wang Lixiong. VEGFR2-V297? site polymorphism and the efficacy and correlation of bevacizumab combined with whole brain radiotherapy in patients with brain metastases from non-small cell lung cancer [J]. Journal of Xuzhou Medical University, 2022,42(4):248-254.
Niu Dehong, Sun Yumei, Yu Fachang. Effect of bevacizumab combined with cisplatin chemotherapy on tumor markers and T lymphocyte subsets in patients with advanced lung cancer [J]. Journal of Mathematics and Medicine, 2022, 35(7) :1045-1047.
Zhang Qilin, Ding Yufeng, Dai Bing, Shu Yamin. Cost-effectiveness analysis of pemetrexed combined with bevacizumab maintenance therapy for advanced non-squamous non-small cell lung cancer [J]. China Pharmaceutical Industry, 2022, 31 (10) ):106-111.
Chen Pengtao, Ai Yan. Clinical efficacy of bevacizumab combined with pleural infusion chemotherapy in the treatment of non-small cell lung cancer complicated with malignant pleural effusion [J]. Journal of Clinical Rational Drug Use, 2022, 15(34): 17-19, 23 .
Yang Hailin, Bai Yingwei, Wei Shaoxian, Xi Ying. The clinical efficacy of bevacizumab combined with radiotherapy in the treatment of brain metastases from lung cancer and its impact on the immune function and tumor markers of patients [J]. Cancer Progress, 2022, 20(18):1892-1895, 1898.
Wu Zhihai, Yang Chuqin. Application and Safety Meta-analysis of Bevacizumab Combined with Chemotherapy in Elderly Patients with Lung Cancer [J]. Chinese Prescription Drugs, 2022,20(6):10-12.
Chen Minbiao, Li Liang, Liao Xuqiang, Huang Xiuming, etc. Effects of bevacizumab combined with pemetrexed and carboplatin neoadjuvant chemotherapy on immune and cognitive function in elderly patients with non-small cell lung cancer[J]. ,2022,7(11):26-29 .
Lu Ruiqi, Xu Hailiang, Wang Lihuan, Song Jianmin, Guo Chang, etc. Clinical research on bevacizumab injection combined with cisplatin in the treatment of lung cancer-related malignant pleural effusion [J]. Chinese Science and Technology Journal Database (Citation Edition) Medicine and Health ,2022,6 ( 4):45-48 .
Chen Haitao, Yang Sensen, Deng Weishang et al. Meta-analysis of the efficacy, safety and immunogenicity of bevacizumab biosimilars and original drugs in the treatment of non-small cell lung cancer[J]. China Pharmacy, 2022 ,33(8):1003-1008 .
Li Qi, He Xiaoqing. Effects of bevacizumab combined with radiotherapy and chemotherapy on inflammatory factors, vascular endothelial growth factor and Let-7 in non-small cell lung cancer [J]. Jilin Medicine, 2022, 43(6): 1573-1574 .